A66

HY-13261		
1166227-08	-2	
C ₁₇ H ₂₃ N ₅ O ₂ S	b ₂	
393.53		
PI3K		
PI3K/Akt/m	TOR	
Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year
	1166227-08 C ₁₇ H ₂₃ N ₅ O ₂ S 393.53 PI3K PI3K/Akt/m Powder	1166227-08-2 C ₁₇ H ₂₃ N ₅ O ₂ S ₂ 393.53 PI3K PI3K/Akt/mTOR Powder -20°C 4°C In solvent -80°C

®

MedChemExpress

SOLVENT & SOLUBILITY

	Mass Solvent Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.5411 mL	12.7055 mL	25.4110 ml
	5 mM	0.5082 mL	2.5411 mL	5.0822 mL
	10 mM	0.2541 mL	1.2706 mL	2.5411 mL
Please refer to the s	olubility information to select the ap	propriate solvent.		
	t one by one: 10% DMSO >> 40% PE ng/mL (6.35 mM); Clear solution	G300 >> 5% Tween-8) >> 45% saline	
Solubility: ≥ 2.5 m	ent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) 5 mg/mL (6.35 mM); Clear solution			
	t one by one: 10% DMSO >> 90% cor	n oil		

BIOLOGICAL ACTIVITY				
Description	A66 is a highly specific and se	lective p110 α inhibitor with an IG	C ₅₀ of 32 nM.	
IC ₅₀ & Target	p110α 32 nM (IC ₅₀)	p110α E545K 30 nM (IC ₅₀)	p110α H1047R 43 nM (IC ₅₀)	p110γ 3480 nM (IC ₅₀)
	PI3K-C2β 462 nM (IC ₅₀)	ΡΙ4Κβ 236 nM (IC ₅₀)		

Product Data Sheet

NH₂

ö

In Vitro	A66 is a potent inhibitor of the wild-type and oncogenic forms of p110α but not other class-I PI3K isoforms ^[1] . The p110α- specific inhibitor A66 (0.7 μM) induces a 75-80% reduction in focus formation by the highly transforming iSH2 mutants KS459delN, DKRMNS560del, and K379E. The p110α-specific inhibitor A66 reduced phosphorylation of Akt on T308 by all p85 mutants ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	The optimal dosing strategy for xenograft studies is determined by investigating the drug pharmacokinetics after a dose of 10 mg/kg of body weight by intraperitoneal injection in CD-1 mice. Despite a short half-life of only 0.42 h, the large C _{max} (8247 nM) of A66 S that is reached 30 min after dosing ensured that the AUC _{0-inf} (area under the curve from zero time to infinity) (6809 nM?h) is similar to that of BEZ-235 (7333 nM?h), which has a longer half-life of 2.73 h. Furthermore, the A66 on SK-OV-3 tumour tissue is tested using a single dose of 100 mg/kg of body weight to determine whether a long-lasting effect of the drug could be achieved on target tissues. These studies show that A66 causes a profound reduction in the phosphorylation of Akt/PKB and p70 S6 kinase, but not of ERK (extracellular-signal-regulated kinase), at both 1 and 6 h after dosing. Levels of A66 in plasma are determined to be 21.1±1.2 µM and 9.1±1.1 µM at 1 and 6 h after drug injection, whereas levels of A66 in the tumor are 22.7±2.1 µM and 16.0±1.3 µM at the same time points ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL	
Kinase Assay ^[1]	IC ₅₀ values are evaluated using the PI3K (human) HTRF Assay. p85α/p110δ is obtained from Invitrogen. All other isoforms are produced in-house by co-expressing full-length human p85α with the indicated human full-length catalytic subunit containing a histidine tag at the N-terminus to allow purification. The PI3Ks are titrated and used at a concentration between their EC ₆₅ -EC ₈₀ values. PI3K activity in immunoprecipitates is assayed using an antibody to the N-SH2 (N-Src homology 2) domain of p85α. Assays for other lipid kinases and protein kinases are performed by the National Centre for Protein Kinase Profiling and Invitrogen Drug Discovery Services ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice ^[1] Age-matched specific pathogen-free Rag1 ^{-/-} or NIH-III mice are subcutaneously inoculated on the right flank with 5×10 ⁶ U87MG, SK-OV-3 or HCT-116 cells in PBS. Tumour diameter as measured by electronic calipers is used to calculate tumour volume (mm ³) based on the formula (L×w ²)×π/6 (where L=longest tumour diameter and w=perpendicular diameter). A66 is administered in 20% 2-hydroxypropyl-β-cyclodextrin in water, whereas BEZ-235 is administered in 10% ethanol. Control mice are administered the A66 dosing vehicle alone. The drugs are dosed by intraperitoneal injection as the free base equivalent at a dosing volume of 10 mL/kg of body weight. For tumour pharmacodynamic studies, mice are administered a single dose of A66 or the control vehicle when tumors reached approximately 8-9 mm in diameter. Animals are killed 1 or 6 h after dosing and the tumors are removed, biopulverized and assayed for protein concentration. For antitumor efficacy studies, dosing began when tumors are well established, averaging approximately 7 mm in diameter. Doses are administered once daily (QD) or twice daily (BID) with injections separated by a minimum of approximately 8 h. Different dosing schedules are used for the three xenograft models depending on the rate of tumor growth and the body weight tolerance of control mice. Animals are dosed daily for 21 days or twice daily for 16 days (SK-OV-3), daily for 14 days (U87MG) and daily for 7 days (HCT-116). Animals are monitored daily for any signs of emerging toxicity and body weight. TGI (tumour growth inhibition) is calculated on the final day of dosing by determining the relative tumour size of drug-treated mice as a percentage of the average relative tumour size of control mice. The statistical significance of TGI values is determined by one-way ANOVA with Bonferroni multiple comparison analysis using GraphPad Prism 5.02. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- EMBO Rep. 2020 Dec 3;21(12):e49756.
- Molecules. 2020 Apr 23;25(8):1980.
- Cytokine. 2020 May;129:155046.
- Harvard Medical School LINCS LIBRARY

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jamieson S, et al. A drug targeting only p110a can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J, 2011, 438(1), 53-62.

[2]. Sun M, et al. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A, 2010, 107(35), 15547-15552.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA